Tempest Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $14.0M | $13.6M | $11.7M | $12.1M | $9.8M | $4.9M | $17.6M |
| Operating Income | — | $-26.6M | $-42.0M | $-29.2M | $-34.6M | $-27.0M | $-19.3M | $-45.4M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | $1.4M | $1.6M | $1.3M | $0 | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | — | $-26.3M | $-41.8M | $-29.5M | $-35.7M | $-28.3M | $-19.2M | $-44.6M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-6.33 | $-19.50 | $-1.91 | $-3.09 | $-2.49 | $-1.71 | $-0.14 |
| EPS (Diluted) | — | $-6.33 | $-19.50 | $-1.91 | $-3.09 | $-2.49 | $-1.71 | $-0.14 |
| Shares Outstanding (Basic) | 14.3M | 4.1M | 2.1M | 15.4M | 11.5M | 11.4M | 11.2M | 438.4M |
| Shares Outstanding (Diluted) | 14.3M | 4.1M | 2.1M | 15.4M | 11.5M | 11.4M | 11.2M | 438.4M |
| Dividends Per Share | — | — | — | — | — | — | $0.00 | $0.00 |